C6K0.F Avalo Therapeutics, Inc.
- Market cap
- EUR 433M
- P/E
- -
- P/B
- 0.92x
- ROE
- -22.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is C6K0.F undervalued?
Graham numberThe Graham number of Avalo Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Avalo Therapeutics, Inc. fundamental analysis
No fundamental analysis for Avalo Therapeutics, Inc. yet.
Avalo Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporate…
Full company profileAvalo Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Avalo Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 5.40M | 18.1M | 1.92M | 441K | 59.0K | 0.00 |
| Gross Profit | 3.91M | 14.6M | 640K | 807K | 59.0K | - |
| Operating Income | -82.1M | -37.4M | -23.4M | -40.9M | -72.9M | -101M |
| EBITDA | - | -37.3M | -23.3M | -40.7M | -72.6M | -101M |
| Net Income | -84.4M | -41.7M | -31.5M | -35.1M | -78.3M | -99.9M |
| EPS | -2,154 | -1,060 | -39 | -3.35 | -4.23 | -1.85 |
| Balance Sheet | ||||||
| Total Assets | 80.2M | 33.4M | 21.0M | 151M | 116M | 481M |
| Total Liabilities | 57.1M | 44.3M | 13.7M | 17.7M | 33.4M | 44.9M |
| Shareholders' Equity | 23.1M | -10.9M | 7.30M | 133M | 83.0M | 437M |
| Cash & Short-term Investments | 54.6M | 13.2M | 7.42M | 135M | 15.9M | 65.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -70.9M | -26.8M | -30.7M | -49.1M | -51.5M | -65.6M |
| Capital Expenditure | 113K | 95.0K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -71.0M | -26.8M | -30.7M | -49.1M | -51.5M | -65.6M |
| Ratios | ||||||
| ROE | -365.5% | - | -431.9% | -26.4% | -94.2% | -22.9% |
| ROA | -105.2% | -124.8% | -150.3% | -23.3% | -67.2% | -20.8% |
| Net Profit Margin | -1,563.1% | -230.8% | -1,639.5% | -7,965.8% | -132,642.4% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Avalo Therapeutics, Inc. dividends
Avalo Therapeutics, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:240 on Dec 29, 2023.
Who owns Avalo Therapeutics, Inc.
- Insiders 1.57%
- Institutions 98.43%
- Public & others 0.00%
- Shares outstanding 57.8M
- Free float 44.3M
Avalo Therapeutics, Inc. company profile
- Company name
- Avalo Therapeutics, Inc.
- Ticker
- C6K0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- 1500 Liberty Ridge Drive, Wayne, PA, United States, 19087
- Phone
- 410 522 8707
- Website
- avalotx.com
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Avalo Therapeutics, Inc. management
10- Dr. Garry A. Neil M.D.President, CEO & Director · born 1954
- Dr. Mittie Doyle FACR, M.D.Chief Medical Officer · born 1965
- Mr. Taylor BoydChief Business Officer · born 1989
- Dr. Solomon H. Snyder M.D.Founder and Chairman of Scientific Advisory Board · born 1939
- Dr. Barbara S. Slusher Ph.D.Founder and Member of Scientific Advisory Board · born 1965
- Mr. Christopher Ryan Sullivan CPACFO & Head of Investor relations · born 1984
- Mr. Paul C. Varki J.D., M.P.HChief Legal Officer · born 1973
- Ms. Ashley IvanowiczSenior Vice President of Human Resources
- Dr. Dino C. Miano Ph.D.Senior Vice President of CMC & Technical Operations
- Ms. Jennifer RileyChief Strategy Officer · born 1975